[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551549":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":10,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Susoctocog Alfa (Genetical Recombination)",null,"Participants will receive Susoctocog Alfa (Genetical Recombination) intravenous injection.",[13],"Drug: Susoctocog Alfa (Genetical Recombination)",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Susoctocog Alfa (Genetical Recombination), Intravenous injection",[9],[20,21],"OBIZUR Intravenous Injection 500","TAK-672",[23],{"name":24,"affiliation":5,"role":25},"Study Director","STUDY_DIRECTOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Takeda Contact","CONTACT","+1-877-825-3327","medinfoUS@takeda.com",[33],{"facility":34,"status":35,"city":36,"state":36,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":10},"Takeda selected site","RECRUITING","Tokyo","Japan","JP",{"type":40,"coordinates":41},"Point",[42,43],139.69171,35.6895,{"lat":43,"lon":42},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100551549","a-survey-of-susoctocog-alfa-genetical-recombination-in-participants-with-acquired-haemophilia-a-100551549",false,"NCT06461533","A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A","General Use-results Survey of OBIZUR for I.V. Injection (All-case Surveillance)","Inclusion Criteria:\n\n\\- All participants with Acquired Haemophilia A, treated with Susoctocog Alfa (Genetical Recombination).\n\nExclusion Criteria:\n\n\\- None","ALL",{"count":56,"type":57},25,"ESTIMATED","OBSERVATIONAL","This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.\n\nThe main aim of the study is to check for side effects related from Susoctocog Alfa (Genetical Recombination) intravenous injection and to check if Susoctocog Alfa (Genetical Recombination) intravenous injection improves bleeding events of AHA.\n\nDuring the study, participants with AHA will take Susoctocog Alfa (Genetical Recombination) intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from Susoctocog Alfa (Genetical Recombination) intravenous injection for up to 90 days after the last dose of study drug or until discontinued (varied from participant to participant).",[61],"Acquired Hemophilia A","2026-08-05",{"date":64,"type":65},"2026-08-07","ACTUAL",{"date":67,"type":65},"2024-06-10",{"date":69,"type":57},"2028-05-31",{"name":5,"class":6},1]